contact us jpkrencn

お知らせ

お知らせ

あなたはここにいる:ホーム > お知らせ

  • 11
    29

    2023

    メディシロンが支援華奥泰がCD 73を標的とするADCで米国臨床承認_HB 0052の研究開発

    華奥泰のパートナーとして、上海美迪西生物医薬株式会社(以下「メディシロン」と略称する)は抗体薬物複合体研究開発サービスプラットフォームとその専門的な技術能力と豊富なプロジェクト経験を活用し、HB 0052の研究開発にGLP基準に適合する薬物動態、安全性評価試験を提供し、プロジェクトの高品質で効率的な推進を保証しました。

  • 05
    07

    2021

    Fully Support the R&D for the Vaccine, Medicilon mRNA Vaccine Bioanalysis Platform

    Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.

  • 04
    25

    2021

    Shanghai Medicilon appoints two department vice presidents

    Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president of pharmacology. 
    Dr. Chunlin Chen, the founder and CEO of Medicilon, welcomed the two and hoped that their participation will bring new innovation and development momentum to Medicilon, bringing a higher level of industry insight and strategic guidance.

  • 04
    19

    2021

    Medicilon assists HG381 to be approved as STING agonist

    HG381 is new molecular entity developed by HitGen based on the DNA-encoded compound Library (DEL) technology and small molecule new drug research and development platform.As a leading R&D partner of HitGen, Shanghai Medicilon Inc. (Medicilon) provided preparation R&D services for HG381. 

  • 03
    29

    2021

    Medicilon assists Livzon to obtain the clinical approval of novel coronavirus vaccine

    Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine" (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003).  V-01 is to prevent diseases caused by novel coronavirus infection.